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Abstract
Background: Severe side effects following ivermectin treatment of onchocerciasis in areas of co-
endemicity with loaisis have been an impediment for the work of the African Programme for
Onchocerciasis Control (APOC) in forested regions of several countries. Doxycycline has been
shown to be effective in the treatment of onchocerciasis and has the added advantages of killing
adult Onchocerca volvulus but neither adult Loa loa nor their microfilariae. This drug therefore offers
great potential for the treatment of onchocerciasis in areas of co-endemicity with loiasis. The
limitation of use of this drug is the duration of treatment that may pose a potential problem with
therapeutic coverage and compliance with treatment. To benefit from the advantages that
doxycycline offers in the treatment of onchocerciasis, it will be necessary to establish an effective
distribution system that can access remote communities. This study assessed the feasibility of a
large-scale distribution of doxycycline for the treatment of onchocerciasis in areas of co-endemicity
with loiasis using a community-directed approach.
Methods: The study was carried out in 5 health areas co-endemic for Onchocerca volvulus and Loa
loa which had no prior experience of the Community Directed Treatment with Ivermectin (CDTI).
The community-directed delivery process was introduced using a cascade mechanism from the
central health system that passed through the regional health delegation, health district and the
health areas. Community health implementers (CHIs) were trained to deliver doxycycline to
community members and, under the supervision of the health system, to monitor and document
drug intake and side effects.
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Results: The community members adhered massively to the process. Of the 21355 individuals
counted, 17519 were eligible for treatment and 12936 were treated with doxycycline; giving a
therapeutic coverage of eligible population of 73.8%. Of the 12936 who started the treatment,
97.5% complied by the end of six weeks. No serious side effect was registered during the six week
treatment.
Conclusion: This study indicates that when empowered the community health implementers can
successfully deliver doxycycline for six weeks for the treatment of onchocerciasis in areas of co-
endemicity with loiasis. The therapeutic coverage and the compliance treatment rate achieved in
this study coupled to the known efficacy of doxycycline on O. volvulus, are indicators that the
strategy involving the mass administration of doxycycline can be used to control onchocerciasis in
those areas of co-endemicity with loiasis where ivermectin may be contraindicated.
Background
Onchocerciasis or river blindness is endemic in many sub-
Saharan African countries, with minor foci in Central and
South America and the Yemen [1]. It is estimated to affect
over 37 million people [2], of whom 500,000 have been
visually impaired and 270,000 blind.
The registration of ivermectin as a drug for the treatment
of onchocerciasis in 1987 raised great hopes for onchocer-
ciasis control in Africa. After successful clinical trials, the
pharmaceutical firm, Merck and Co, undertook to provide
the drug free of charge as long as it was needed for the
treatment of onchocerciasis. A new strategy involving a
large-scale mass distribution of ivermectin to endemic
communities [3] was rapidly put in place by APOC with
an objective to eradicate onchocerciasis as a public health
problem, and a barrier to socio-economic development
through a community-directed treatment approach.
Using this approach, over 60 million people were receiv-
ing regular treatment for onchocerciasis by the end of
2008, close to one million disability-adjusted life years
have been averted, the prevalence of infection has reduced
by about 73% compared with pre-APOC levels. [4].
However, during mass treatment of onchocerciasis with
ivermectin in forested zones of Central Africa regions
(mainly in Cameroon and the Democratic Republic of
Congo), several cases of adverse reactions (encephalitis,
neurologic disorders, coma and death) post-ivermectin
treatment were reported in patients infected with L. loa
[5,6]. These adverse reactions appear to be associated with
high intensity of infection with L loa [7] and are a con-
straint on the implementation of CDTI in areas endemic
for O. volvulus and L. loa.
The development and validation of the rapid assessment
procedure for loiasis (RAPLOA) to delineate communities
at risk of severe adverse reactions to ivermectin treatment
was a step towards solving this problem [8]. In addition,
guidelines have been developed by the Mectizan® Expert
Committee (MEC) and the APOC Technical Consultative
Committee (TCC) and recommend special monitoring of
treatment in areas where the RAPLOA prevalence is above
40% [9]. This notwithstanding, due to the remoteness of
some communities in areas of co-endemicity, some cases
of severe adverse effects are never detected or treated on
time and have sometimes resulted in deaths. Furthermore,
ivermectin is only microfilaricidal and there is growing
concern that the low success of mass treatment in some
areas may, in part, be due to existence of O. volvulus
worms that show a sub- optimal response to ivermectin
[10,11]
These observations have prompted a search for new filar-
icides which could substitute ivermectin in areas of co-
endemicity and/or could be used to treat onchocerciasis
without affecting L. loa. In this regard, the discovery of
Wolbachia endobacteria in all pathogenic human filarial
nematodes [12,13] but not L. loa [14,15] presented an
opportunity to take a novel approach to onchocerciasis
treatment based on use of antibiotics to target the endo-
bacteria [[16,17], and [18]]. Such strategies have now
been shown to be effective in both the long-term reduc-
tion of parasite loads and morbidity [18]. In animal stud-
ies, it was observed that depletion of the Wolbachia using
tetracycline not only had microfilaricidal effects but also
led to the sterility of female worms [16]. Similarly in
humans, a 6-week course of doxycycline treatment against
O. volvulus depleted the bacteria, resulted in a blockage of
embryogenesis and killed the adult worms. These effects
were reflected in sustained reductions in skin microfilar-
iae [19-21]. These findings have demonstrated the supe-
rior pharmacological efficacy of doxycycline for
onchocerciasis. [22] Macrofilaricides have a higher poten-
tial for sustainable onchocerciasis control but this can be
only guaranteed through high coverage and compliance
[23]. This is particularly important for a drug such as dox-
ycyline that must be taken on a daily basis for 6 weeks.
The argument for mass treatment with doxycycline in
areas of co-endemicity with O. volvulus/L. loa relies heavily
on its selective toxicity for O volvulus and the absence of
adverse reactions due to lack of action on L. loa. However,Parasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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its acceptance as a complementary tool for mass treatment
of onchocerciasis will very much depend on development
of effective strategies for delivery to target communities.
In a recent multi-country study carried out in five African
countries, it has been demonstratated that the commu-
nity-directed approach can be used to deliver ivermectin
and other more complex health interventions in an inte-
grated manner [24]. This study was designed to assess the
feasibility of a large-scale delivery of doxycycline using the
community-directed approach for the treatment of
onchocerciasis in areas of co-endemicity with loiasis, with
the specific objectives being to determine the therapeutic
coverage, the compliance rate and to document the side
effects associated with the treatment.
Methods
Study design
The study was carried out with communities in the
Mbanga and Melong health districts in the littoral region
of Cameroon from November 2006 to October 2008.
These communities have never received mass treatment
with ivermectin. A cascade mechanism involving advo-
cacy meetings with all stakeholders (health system and
community members) was used to introduce the commu-
nity directed delivery process to the population in
onchocerciasis/loiasis co-endemic areas. Community
health implementers selected by community members
were trained to deliver doxycycline to the community
members and to document the treatment coverage, com-
pliance and side effects. This work was carried out under
the supervision of the health system. Treatments took
place in June 2007 and in July 2008 for those who missed
treatment in 2007.
Study sites
Melong Health District
This health district covers a land area of 641 km2 with an
estimated population of 122,925 inhabitants and com-
prises 10 health areas. The health areas selected for the
study included Mbokambo and Essekou. The health area
of Mbokambo covers an area of 98 km2 with an estimated
population of 4128 inhabitants while Essekou covers an
approximate area of 75 km2 with an estimated population
of 3244 inhabitants. Mbokambo and Essekou are situated
in a forest zone.
Mbanga Health District
This District covers an area of 540 km2 with an estimated
population of 58,244 inhabitants and comprises 8 health
areas. The health areas selected for the study included
Matouke, Kotto and Mombo. These health areas are situ-
ated along the Mungo River which represents a potential
breeding site for Simulium. The health area of Matouke is
mainly occupied by the Cameroon Development Corpo-
ration (CDC) workers and has about 7183 inhabitants,
Kotto 2542 inhabitants and Mombo 4258 inhabitants.
In both districts the main occupation is farming and the
major cash crops are rubber, cocoa, coffee and oil palm,
while food crops include cassava, groundnuts, plantains,
maize and beans. The autochthonous ethnic group is Mbo
but many other tribal groups (Bamileke, Esimbi, Ngi, Bat-
ibo) are present.
Selection of study communities
A rapid epidemiological survey was conducted in the
study sites to confirm the endemicity of L. loa and O. vol-
vulus. The combined RAPLOA and Rapid epidemiological
assessment of onchocerciasis (REA) protocol was used to
assess the prevalence of loiasis and onchocerciasis [25].
The results obtained from this survey guided the selection
of three health areas from Mbanga health district
(Matouke, Kotto and Mombo) and two from Melong
health district (Essekou and Mbokambo).
Introduction of the community directed intervention
Advocacy meetings on the community-directed treatment
with doxycycline were held with the health system at the
central, regional, district levels and front-line health facil-
ities. These meetings brought together representatives of
the Ministry of Health, National Onchocerciasis Task
Force (NOTF), Non-governmental organisations (NGO)
involved in the control of onchocerciasis and the health
personnel. During these meetings the project objectives
were presented to the different partners and its philoso-
phy. The role of each partner in the process was discussed
and their adherence to the process was sought. Discus-
sions also focused on the disease onchocerciasis, its socio-
economic impact and its control in Cameroon.
At the community levels, social mobilisation meetings
were organised in each community selected for the study
to sensitise the community leaders and their subjects on
the community-directed treatment process. Participants
in these meetings were the community leaders and their
populations, personnel of the district health service, the
staff of the front line health facilities (FLHF) and social
scientists. Discussions were done principally in Pidgin
English and when necessary, translations were made into
local languages.
Training of Community Health Implementers
Community Health Implementers were selected by the
community members and were trained to dispense doxy-
cycline to community members. CHIs were also trained
to: i, carry out census exercises; ii, to determine eligibility
of patients for the treatment; iii, to determine treatment
dosage; iv, complete treatment registers; and, v, identify
and report of side effects. Training sessions were organ-Parasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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ized in the front-line health facilities. The training was
done by the staff of the district health service and the med-
ical personnel of the FLHF under the supervision of the
research team.
A population census followed training of CHIs. Census
was done in each community by the community health
implementer. In each household all individuals were
recorded. Information on age, sex, occupation and time
spent in the community was collected from each individ-
ual. For adult females additional information on preg-
nancy or breastfeeding status was collected. This exercise
was monitored by the medical personnel and the research
team.
Delivery of intervention
Doxycycline tablets (Vibramycin®) were from the Pfizer
Company through the German medical aid organization
e.v Action Medeor. The treatment regimen was 100 mg
tablet per day for 42 days. Eligibility criteria for treatment
included: individuals aged 12 years and above; resident in
the community; not suffering from any chronic disease
(hypertension, tuberculosis, diabetes, AIDS); not preg-
nant and not breastfeeding women. Doxycycline is not
prescribed to children less than 9 years of age because it
interferes with the growth of teeth. The choice of 12 years
as an age limit was recommended by the institutional
review board (IRB) as a measure to minimize a potential
risk for participants. To ease the work of the community
health implementers, the drugs were pre-packaged at the
community pharmacies of the front- line health facility in
appropriate daily and weekly individual doses before the
commencement of treatment.
The treatment strategy adopted was door-to-door. Each
week the CHI collected the week's dose from the FLHF
staff and proceeded with the treatment making sure that
each participant ate something before swallowing the tab-
let. Each treatment was recorded in a treatment register.
Ethical and administrative clearance
This study was approved by the Ministry of Public Health
of Cameroon who issued an administrative clearance (N°
D30-70/L/MSP/SG/DRO/CRC). The ethical clearance was
obtained from the institutional review board of the Trop-
ical Medicine Research Station, Kumba, Cameroon. Com-
munities and individuals who participated in the study
gave their written informed consent.
Monitoring and evaluation of treatment
The monitoring of drug intake by the patients was done
on a daily basis by the CHIs and on a weekly basis by the
staff of the FLHF and the research team. The staff of the
FLHF and the District medical officer addressed issues of
side effects reported by CHIs. At the end of the exercise, all
treatment registers were retrieved for the compilation of
data. Treatment records and supervision reports were used
to evaluate the treatment coverage and population com-
pliance with treatment [26,27].
Social scientists carried out in-depth interviews with
health personnel, community leaders and community
health implementers, while focus-group discussions were
conducted with community members to assess their atti-
tudes towards the treatment process.
Data processing
Treatment data were entered in a template developed in
Epi Info 6 and analyzed in SPSS Version 15. The analysis
consisted in determining the therapeutic coverage and
compliance with doxycycline treatment. Two types of
therapeutic coverage were determined:
- the general therapeutic coverage was defined as the pro-
portion of individuals treated in the total population cen-
sured;
- the therapeutic coverage of the eligible population was
defined as the proportion of individuals that were treated
in the eligible population.
Compliance was defined as the proportion of individuals
who completed the six weeks' treatment without missing
a single treatment.
The side effects observed during treatment and the fre-
quency of occurrence of each were recorded.
Results
Endemicity of onchocerciasis and loiasis in the study site
The five health areas selected for the study were endemic
for onchocerciasis and loiasis. Onchocerciasis was meso-
or hyper- endemic in all the health areas with prevalence
varying from 22% in Mbokambo to 49.7% in Matouke.
The prevalence of loiasis varied from 17.9% in Matouke to
48.9% in Mombo (Table 1).
Introduction of the Community-directed intervention 
(CDI) process
Advocacy meetings at national, regional, health district
and FLHF levels were very important to explain the philos-
ophy of CDI and to seek commitment of stakeholders.
The Ministry of Health issued an administrative clearance
and instructed the Division of Operational Research at the
Ministry of Public Health to monitor the study in the
field. The National Onchocerciasis Control Programme
(NOCP) demonstrated its commitment and agreement to
the process by exempting the study sites from its own
CDTI activities and by participating in advocacy and resti-
tution meetings. The Health System graciously integratedParasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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into their agenda the calendar of research activities. The
Health System took part in all activities from advocacy
meetings to the training of CHIs, pre-packaging of drugs,
social mobilization, and introduction of the intervention
in the communities and monitoring of the treatment.
Training of community health implementers and 
population census
Community health implementers were trained and
rotated during the second phase of the study. A total of 96
CHIs were trained in the health district of Mbanga and 94
in the health district of Melong. Table 2 gives the number
of CHI trained in different health areas.
Table 3 gives the population structure following a general
census conducted. 21355 individuals were censured. In
all, 17519 individuals were eligible for treatment. Of the
3836 individuals who were not eligible for treatment,
3354 (15.7%) were below 12 years, 435 (2.0%) were
pregnant or breastfeeding women and 47 (0.22%) were
individuals with chronic diseases (Table 3).
Therapeutic coverage and compliance with treatment
Of the 21355 individuals censused, 17519 were eligible
for the treatment of which 12936 were treated with doxy-
cycline, giving a general therapeutic coverage of 60.6%
and a therapeutic coverage per eligible population of
73.83%. Table 4 gives the eligible population and the
therapeutic coverage achieved during the two phases.
Of the 12936 individuals that started treatment in the
study area, 12612 completed the 6 weeks treatment with-
out missing a single treatment, giving a compliance rate of
97.5%. The compliance rates varied from 95.46% in Kotto
to 99.52% in Matouke (Table 5).
560 individuals dropped out of treatment (462 in the first
phase and 98 in the second phase). 92 individuals who
dropped out of the treatment in the first phase took part
and completed the treatment in the second phase. Rea-
sons for dropping out of the treatment after beginning of
treatment were: pregnancy (1.9%); travel out of the village
(18.75%); abandoned with no reason advanced (69.3%)
and sickness (10.0%).
Table 1: Endemicity of L. loa and O. volvulus in the study areas
RAPLOA (Loiasis) REA (Onchocerciasis)
Health District Health Area No. examined Prevalence (%) No. examined Prevalence (%)
Mbanga K o t t o 2 8 23 2 . 1 9 04 8 . 3 6
Matouke 480 17.93 185 49.72
Mombo 466 48.95 159 41.5
Melong Essekou 234 54.13 112 22.73
Mbokambo 449 40.39 223 22.04
Table 2: Community Health Implementers trained and recycled in different health areas
Health district Health areas Number of study communities Number of CHI trained 
in first phase
Number of CHI recycled or 
trained in the second phase
Mbanga Kotto 3 15 11
Matouke 9 48 45
Mombo 6 35 24
Melong Essekou 4 35 27
Mbokambo 13 57 59
Total 35 190 166Parasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
Page 6 of 10
(page number not for citation purposes)
There was no significant difference in the compliance rate
with respect to the age and sex of individuals.
Side effects following doxycycline treatment
Of the 371 cases of side effects recorded during the treat-
ment, 270 (72.8%) cases were side effects that are well
known and associated with doxycycline intake including:
nausea (137.4%); mild diarrhoea (12.6%); vomiting
(13.7%); loss of appetite (1.1%); mild skin rash (5.9%);
joint pains (7.4%); fever (4.1%); headache (6.2%);
blurred vision (2.2%); and, feeling tired (9.2%).
101 (27.2%) cases reported: body pains (22.8%); boils;
increase appetite (7.9%); feeling sleepy (9.9%); and, body
itches (59.4%). Apart from one patient who received anti-
inflammatory drugs to treat a swollen arm, these side
effects were generally mild and subsided without any
intervention or interruption of treatment.
Discussion
The occurrence of severe adverse reactions in loiasis
patients following ivermectin treatment [5,6] has raised
major concerns for Community Directed Treatment with
Ivermectin programmes situated in areas of co-endemic-
ity. As a consequence, it has become necessary to identify
new filaricides, and one approach has been to find a drug
that can kill O. volvulus but not L. loa. There is sufficient
scientific evidence proving the efficacy of doxycycline in
the treatment of onchocerciasis [16,17,19,21,22] and crit-
ically, this drug is both micro- and macro-filaricidal for O.
volvulus and has no effect on L. loa [14].
Unlike ivermectin, which requires just a single dose, dox-
ycyline requires a course of treatment lasting 5 to 6 weeks
and this presents logistical problems [28]. The main chal-
lenge remained its delivery to remote communities given
its long treatment regimen. This study, which is not a clin-
Table 3: Population structure after the census.
Non-eligible for treatment
Health district Health areas Population 
censused
Children below 
12 years
Pregnant/
breast feeding
women
Individuals with 
chronic diseases*
Eligible for 
treatment
Mbanga Kotto 2542 415 53 6 2068
Matouke 7183 800 123 13 6247
Mombo 4258 462 71 1 3724
Melong Essekou 3244 636 94 24 2490
Mbokambo 4128 1041 94 3 2990
Total 21355 3354 435 47 17519
* Chronic diseases included: Tuberculosis, AIDS, Hypertension, Diabetes or individuals on long-term antibiotics therapy.
Table 4: Treatment coverage of the general and eligible population in different health areas
Health district Health areas Population 
censused
Eligible 
population
Eligible 
population 
treated
General 
treatment 
coverage
Treatment 
overage of eligible 
population
Mbanga Kotto 2542 2068 1768 69.55 85.49
Matouke 7183 6247 4737 65.95 75.83
Mombo 4258 3724 2339 54.93 62.81
Melong Essekou 3244 2490 1885 58.11 75.70
Mbokambo 4128 2990 2207 53.46 73.81
Total 21355 17519 12936 60.58 73.84Parasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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ical trial, was designed to test the feasibility of delivering
doxycycline to communities using a community directed
approach, a method that has previously proved effective
and sustainable in the delivery of ivermectin, impregnated
bed nets, and antimalarial drugs [3,24].
Therapeutic coverage and implications for the mass 
administration of doxycycline for the control of 
onchocerciasis
In this study, using the CDI approach to deliver doxycy-
cline, we achieved a general therapeutic coverage of
60.6% and a therapeutic coverage per eligible population
of 73.8%. A high therapeutic coverage is a prerequisite for
success of any disease control programme. The therapeu-
tic coverage achieved in this study is high and augurs well
for encouraging for a subsequent implementation of a
large-scale distribution of doxycycline for the treatment of
onchocerciasis in areas co-endemic with L. loa. With a
yearly coverage of 65% the African programme for
onchocerciasis control recommends 12 to 15 years of
treatment with ivermectin (ivermectin is only microfilari-
cidal) to eradicate onchocerciasis [29]. Doxycycline com-
bines the properties of being both a macro and
microfilaricide on O. volvulus with 60 to 65% of the
female worms dying following a six week treatment [30]
(Turner DJ, Tendongfor N, Esum M, Johnston KL, Langley
RS, Ford L, Faragher B, Walker B, Whitehead J, Specht S,
Mand S, Hoerauf A, Enyong P, Wanji S, Taylor MJ: Macro-
filaricidal activity after doxycycline treatment of
Onchocerca volvulus in people co-infected with Loa loa: a
randomized, double-blind, placebo controlled trial,
PLOS NTD, Submitted). It acts on embryogenesis in female
worms leading to complete sterility before the death of
female worms [16]. Doxycycline retards the development
of O. volvulus larvae in the vector as microfilariae depleted
from Wolbachia endosymbiotic bacteria develop poorly
in Simulium sp (Anna Albers, Mathias Eyong Esum, Ten-
dongfor N, Enyong P, Wanji S, Hoerauf A, Pfarr K:
Retarded Onchocerca volvulus L1 to L3 larval develop-
ment in the Simulium damnosum vector after anti-wol-
bachial treatment of the human host.  Int. Journal of
Parasitology, Submitted). Mathematical simulations show
that macrofilaricidal drugs have higher potential of
achieving elimination of onchocerciasis and require less
number of rounds of mass drug administration [31]. It
can therefore be anticipated that with a general therapeu-
tic coverage of 60% achieved with the community-
directed administration of doxycycline it may require less
round of mass drug administration to bring the commu-
nity microfilarial load of O. volvulus below the threshold
level of transmission in a given endemic area. Neverthe-
less, it is necessary to develop a mathematical model
based on data generated so far to determine the number
of rounds as well as the periodicity of mass administration
of doxycycline for the control of onchocerciasis.
High treatment compliance rate and lack of severe side 
effects as indicators of sustainability for the large-scale use 
of doxycycline through the community-directed approach
Complying or conforming to treatments is absolutely nec-
essary for effective medical treatment to have its desired
effects. Good compliance to treatment is dependent on
the willingness and motivation of patients to follow the
regimens prescribed, which is based on the information
about the medication received by the patient, the com-
plexity of the regimen, the side effects and the benefits
they may derive from the treatment [32-34]. In this study
97.5% of the people who started treatment effectively
completed it. This compliance was high despite the long
regimen of doxycycline and also is a good indicator that
doxycycline can be mass administered for the control of
onchocerciasis using a community directed approach. The
compliance rate did not vary with age or sex of the treated
population. This is an indication of good acceptability of
the drug by all categories of individuals in the commu-
nity. Community members reported that doxycycline
relieves them from body itches, nodules, improved their
vision, increased their appetite and sexual desire, cured
Table 5: Compliance rate of the population with the 6 weeks treatment with doxycycline in the different health areas.
Health district Health areas Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Overall
Mbanga Kotto 99.77 96.98 95.37 94.48 93.49 92.67 95.46
Matouke 99.96 99.69 99.58 99.42 99.29 99.21 99.52
Mombo 100.00 99.51 99.19 98.70 98.21 97.95 98.93
Melong Essekou 99.85 97.64 96.25 94.94 94.01 93.81 96.11
Mbokambo 99.89 99.00 97.89 96.64 96.03 95.62 97.49
Total 99.89 98.56 97.66 96.83 96.20 95.85 97.50Parasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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boils and wounds. The positive feed-back from commu-
nity members who took part in the first phase of treat-
ment motivated reluctant individuals to adhere to
treatment in the second phase. Some individuals who
took the treatment in the first phase were very willing to
repeat in the second phase as a result of the benefits
derived "many people are asking for the drugs in my commu-
nity and those who have already been treated are still requesting
for another treatment" said one CHI in Sanke. Doxycycline
being a broad spectrum antibiotic, in addition to its filar-
icidal effect, had extended effects on some common bac-
terial infections. Pregnancy, travel, illness and fear of side
effects were the main reasons for refusing or interrupting
the treatment.
Several factors accounted for the high compliance rate
achieved in this study. The social awareness campaigns in
which the population was well informed on the process
and the role to play in the process contributed much to its
success. The fact that each partner in the CDI process ade-
quately played his or her role was an important factor for
success. The awareness of the burden of the disease
onchocerciasis and its socio-economic impacts on the
population was a motivating factor for community adher-
ence and compliance to treatment "before the advent of dox-
ycycline distribution, filarial was more serious than any other
disease in this community" declared a community member.
The fact that the drug was delivered by CHIs selected by
community members guaranteed some trust and was a
great motivating factor in the population's adherence and
compliance with the treatment. It is known that interven-
tions delivered by the community health workers are
more accepted by the population than those delivered
using the normal health system [35] and that it signifi-
cantly improves the accessibility of the treatment and
treatment seeking behaviour of community members
[36,37].
The free distribution of the drug was also an encouraging
factor for the population to accept and adhere to the treat-
ment. The positive effects experienced by those who took
the drug motivated others to request for their own treat-
ment, "I used to have a nodule on my knee, but it has disap-
peared after doxycycline treatment", declared a notable of the
Mbokambo community who took the treatment 24
months ago.
Doxycycline today offers a good alternative to ivermectin
in the treatment of onchocerciasis in areas of co-endemic-
ity with loiasis. In fact during the six weeks mass treatment
with doxycycline, the side effects recorded were generally
well known side effects associated with doxycycline intake
(nausea, diarrhoea, vomiting, skin rash blurred vision,
and headache). These side effects were mild and subsided
without any medical intervention or interruption of the
treatment. This study has largely demonstrated that the
intake of doxycycline at a large scale is accompanied by
mild side effects and this can justify the use of this drug to
treat onchocerciasis in areas where O. volvulus and L. loa
co-exist. The high compliance rate recorded in this study
and the lacks of severe side effects are good indicators that
the mass administration of doxycycline for the treatment
of onchocerciasis in areas of co-endemicity of loiasis can
be a sustainable activity.
Potential advantage in cost-effectiveness of the 
community-directed approach
In order for any health intervention to achieve its goal, the
intervention must be cost-effective. That is affordable to
the health system, donors or community members. Policy
and decision makers are increasingly requesting informa-
tion on cost-effectiveness to minimise cost of interven-
tions and to efficiently allocate health resources. Few
studies have investigated the cost effectiveness of commu-
nity- based interventions. A recent multi-country study on
community-directed interventions for major health prob-
lems in Africa involving eight research teams from five
African countries demonstrated that community-directed
interventions is more cost-effective than conventional
delivery systems for the integrated delivery of vitamin A,
insecticide treated nets and antimalarial drugs [24]. With
lower implementation costs, the community directed
approach achieved higher coverage than the conventional
delivery system at the health district and front line health
facility levels. Other more recent studies confirmed those
findings with community based interventions producing
economic savings and health benefits that are sustained
over long period [37-39]. Though our study was not
designed to measure the cost of large- scale delivery of
doxycycline, it is very likely that the implementation of
the delivery of doxycycline using the community-directed
approach will be more cost- effective than if it were to be
done with the conventional delivery system at the health
district and front-line health facility levels. One important
consideration for the large scale use of doxycycline for the
treatment of onchocerciasis is the fact that this drug is not
presently made available free of charge as compared to
ivermectin. The cost (purchase and delivery) of the six
week treatment per patient is estimated at $ 2.5 (data not
shown). Given the fact that most of the onchocerciasis
patients living in endemic communities have income
below the poverty level; this estimated cost may be a seri-
ous barrier to their accessibility to this therapy. It would
therefore be necessary for the health systems of endemic
countries to subsidise the cost of doxycycline for the end-
users in the large scale treatment of onchocerciasis where
appropriate.
Conclusions and perspectives
This study indicates that, when empowered, the commu-
nity health implementers can successfully deliver doxycy-
cline for six weeks for the treatment of onchocerciasis inParasites & Vectors 2009, 2:39 http://www.parasitesandvectors.com/content/2/1/39
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areas of co-endemicity with loiasis. The therapeutic cover-
age and the compliance treatment rate achieved in this
study coupled to the known efficacy of doxycycline on O.
volvulus, are indicators that the strategy involving the mass
administration of doxycycline can be used to control
onchocerciasis in those areas of co-endemicity with loiasis
where ivermectin may be contraindicated. Such commu-
nity-directed approach is likely to be more cost-effective
than the one achieved through conventional health sys-
tem. It is necessary to develop a mathematical model
based on data generated from this study coupled to other
studies on efficacy of doxycycline on O. volvulus both in
the human host and Simulium vector to define the number
of rounds and the periodicity of mass administration of
doxycycline to control onchocerciasis.
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